Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy

Parkinsonism and Related Disorders

Volumn 14, Issue 8, 2008, Pages 600-607

  Goldstein, David S ^a   Holmes, Courtney ^a   Bentho, Oladi ^a   Sato, Takuya ^a   Moak, Jeffrey ^b   Sharabi, Yehonatan ^a   Imrich, Richard ^a   Conant, Shielah ^c   Eldadah, Basil A ^a,b,c  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Biomarker; DOPAC; Fluorodopa; Fluorodopamine; Multiple system atrophy; Parkinson; PET

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; 6 FLUORODOPA F 18; BIOLOGICAL MARKER; CARBIDOPA PLUS LEVODOPA; CATECHOL; DIHYDROXYPHENYLACETIC ACID; DOPA; DOPAMINE; NORADRENALIN;

ADULT; AGED; ANOSMIA; ARTICLE; BLOOD LEVEL; BRAIN TOMOGRAPHY; CAUDATE NUCLEUS; CENTRAL DOPAMINE DEFICIENCY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; HEART MUSCLE; HEART VENTRICLE SEPTUM; HUMAN; MAJOR CLINICAL STUDY; NEUROCHEMISTRY; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RADIOACTIVITY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; SMELLING; SUBSTANTIA NIGRA;

3,4-DIHYDROXYPHENYLACETIC ACID; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BRAIN; DIHYDROXYPHENYLALANINE; DOPAMINE; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HEART SEPTUM; HUMANS; MALE; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

EID: 55749107827     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.01.010     Document Type: Article

References (41)

1. Ravina B., Eidelberg D., Ahlskog J.E., Albin R.L., Brooks D.J., Carbon M., et al. The role of radiotracer imaging in Parkinson disease. Neurology 64 (2005) 208-215
2. Hoshi H., Kuwabara H., Leger G., Cumming P., Guttman M., and Gjedde A. 6-[18F]Fluoro-l-dopa metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab 13 (1993) 57-69
3. Otsuka M., Kuwabara Y., Ichiya Y., Hosokawa S., Sasaki M., Yoshida T., et al. Differentiating between multiple system atrophy and Parkinson's disease by positron emission tomography with 18F-dopa and 18F-FDG. Ann Nucl Med 11 (1997) 251-257
4. Goldstein D.S., Imrich R., Peckham E., Holmes C., Lopez G., Crews C., et al. Cardiac sympathetic denervation, baroreflex failure, and nigrostriatal dopamine deficiency in Parkinson disease from LRRK2 gene mutation. Neurology 69 (2007) 1580-1584
5. LeWitt P.A., Galloway M.P., Matson W., Milbury P., McDermott M., Srivastava D.K., et al. Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group. Neurology 42 (1992) 2111-2117
6. Eldrup E., Mogensen P., Jacobsen J., Pakkenberg H., and Christensen N.J. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease. Acta Neurol Scand 92 (1995) 116-121
7. Litvan I., Goetz C.G., Jankovic J., Wenning G.K., Booth V., Bartko J.J., et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 54 (1997) 937-944
8. Wenning G.K., Ben-Shlomo Y., Magalhaes M., Daniel S.E., and Quinn N.P. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatr 58 (1995) 160-166
9. Antonini A., Leenders K.L., Vontobel P., Maguire R.P., Missimer J., Psylla M., et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 120 Pt 12 (1997) 2187-2195
10. Polinsky R.J., Brown R.T., Burns R.S., Harvey-White J., and Kopin I.J. Low lumbar CSF levels of homovanillic acid and 5-hydroxyindoleacetic acid in multiple system atrophy with autonomic failure. J Neurol Neurosurg Psychiatr 51 (1988) 914-919
11. Senard J.M., Brefel-Courbon C., Rascol O., and Montastruc J.L. Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 18 (2001) 495-505
12. Goldstein D.S. Orthostatic hypotension as an early finding in Parkinson disease. Clin Auton Res 16 (2006) 46-64
13. Schocke M.F., Seppi K., Esterhammer R., Kremser C., Jaschke W., Poewe W., et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 58 (2002) 575-580
14. Kollensperger M., Seppi K., Liener C., Boesch S., Heute D., Mair K.J., et al. Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord (2007)
15. Behnke S., Berg D., Naumann M., and Becker G. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatr 76 (2005) 423-425
16. Baldessarini R.J., Marsh E.R., Kula N.S., Zong R.S., Gao Y.G., and Neumeyer J.L. Effects of isomers of hydroxyaporphines on dopamine metabolism in rat brain regions. Biochem Pharmacol 40 (1990) 417-423
17. Hurd Y.L., Suzuki M., and Sedvall G.C. D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain. J Chem Neuroanat 22 (2001) 127-137
18. Orimo S., Ozawa E., Oka T., Nakade S., Tsuchiya K., Yoshimoto M., et al. Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 57 (2001) 1140-1141
19. Orimo S., Oka T., Miura H., Tsuchiya K., Mori F., Wakabayashi K., et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatr 73 (2002) 776-777
20. Amino T., Orimo S., Takahashi A., Uchihara T., and Mizusawa H. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol 15 (2005) 29-34
21. Orimo S., Kanazawa T., Nakamura A., Uchihara T., Mori F., Kakita A., et al. Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol (Berl) 113 (2007) 81-86
22. Siderowf A., Newberg A., Chou K.L., Lloyd M., Colcher A., Hurtig H.I., et al. [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 64 (2005) 1716-1720
23. Lee P.H., Yeo S.H., Kim H.J., and Youm H.Y. Correlation between cardiac 123I-MIBG and odor identification in patients with Parkinson's disease and multiple system atrophy. Mov Disord 21 (2006) 1975-1977
24. Abele M., Riet A., Hummel T., Klockgether T., and Wullner U. Olfactory dysfunction in cerebellar ataxia and multiple system atrophy. J Neurol 250 (2003) 1453-1455
25. Nee L.E., Scott J., and Polinsky R.J. Olfactory dysfunction in the Shy-Drager syndrome. Clin Auton Res 3 (1993) 281-282
26. Kaufmann H. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res 6 (1996) 125-126
27. Gilman S., Low P., Quinn N., Albanese A., Ben-Shlomo Y., Fowler C., et al. Consensus statement on the diagnosis of multiple system atrophy. Clin Auton Res 8 (1998) 359-362
28. Goldstein D.S., and Tack C. Non-invasive detection of sympathetic neurocirculatory failure. Clin Auton Res 10 (2000) 285-291
29. Goldstein D.S., Holmes C., Li S.T., Bruce S., Metman L.V., and Cannon III R.O. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 133 (2000) 338-347
30. Goldstein D.S., Holmes C., Patronas N., and Kopin I.J. Cerebrospinal fluid levels of catechols in patients with neurogenic orthostatic hypotension. Clin Sci (Lond) 104 (2003) 649-654
31. Holmes C., Eisenhofer G., and Goldstein D.S. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 653 (1994) 131-138
32. Goldstein D.S., and Holmes C. Metabolic fate of the sympathoneural imaging agent 6-[18F]fluorodopamine in humans. Clin Exp Hypertens 19 (1997) 155-161
33. Lang A.E., and Garnett E.S. Dopa-responsive parkinsonism with normal 6[18F]-fluorodopa positron emission tomography scans. Ann Neurol 28 (1990) 592-593
34. Brooks D.J., Salmon E.P., Mathias C.J., Quinn N., Leenders K.L., Bannister R., et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 113 Pt 5 (1990) 1539-1552
35. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20 (1973) 415-455
36. Wilson J.M., Levey A.I., Rajput A., Ang L., Guttman M., Shannak K., et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47 (1996) 718-726
37. Kish S.J., Shannak K., and Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318 (1988) 876-880
38. Spokes E.G.S., Bannister R., and Oppenheimer D.R. Multiple system atrophy with autonomic failure: clinical, histological and neurochemical observations on four cases. J Neurol 43 (1979) 59-82
39. Muller A., Mungersdorf M., Reichmann H., Strehle G., and Hummel T. Olfactory function in Parkinsonian syndromes. J Clin Neurosci 9 (2002) 521-524
40. Seppi K., Schocke M.F., Donnemiller E., Esterhammer R., Kremser C., Scherfler C., et al. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. Mov Disord 19 (2004) 1438-1445
41. Goldstein D.S., Eisenhofer G., Dunn B.B., Armando I., Lenders J., Grossman E., et al. Positron emission tomographic imaging of cardiac sympathetic innervation using 6-[18F]fluorodopamine: initial findings in humans. J Am Coll Cardiol 22 (1993) 1961-1971